InsiderTrades.com logo
How Low-Cost Stocks Generate Monthly Income
From Darwin   |   Ad
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
👉 Yes, I Want the Free Report! 👈

MBX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $18,000,000.00
Insider Selling (Last 12 Months): $0.00

MBX Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at MBX Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MBX Biosciences Share Price & Price History

Current Price: $21.89
Price Change: ▲ Price Increase of +0.33 (1.53%)
As of 12/26/2024 06:23 PM ET

This chart shows the closing price history over time for MBX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Has Trump Finally Gone Too Far?
From Insiders Exposed   |   Ad
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Register For The Webinar To Discover

MBX Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/16/2024Edward T MathersDirectorBuy500,000$16.00$8,000,000.003,614,486View SEC Filing Icon  
9/16/2024Life Sciences X L.P. FrazierMajor ShareholderBuy625,000$16.00$10,000,000.004,552,774View SEC Filing Icon  
See Full Table
We recommended Palantir in 2021, now we’re recommending this...
From Behind the Markets   |   Ad
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Click to get the name and ticker symbol

SEC Filings (Institutional Ownership Changes) for MBX Biosciences (NYSE:MBX)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MBX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

MBX Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/27/2024Franklin Resources Inc.450,000$11.69M0.0%N/A1.346%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC16,400$0.43M0.0%N/A0.049%Search for SEC Filing on Google Icon
11/18/2024Teachers Retirement System of The State of Kentucky26,708$0.69M0.0%N/A0.080%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC22,269$0.58M0.0%N/A0.067%Search for SEC Filing on Google Icon
11/15/2024Frazier Life Sciences Management L.P.5,985,347$155.50M6.2%N/A17.909%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC16,400$0.43M0.0%N/A0.049%Search for SEC Filing on Google Icon
11/15/2024Jane Street Group LLC26,570$0.69M0.0%N/A0.080%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP2,937,853$74.26M0.0%N/A8.791%Search for SEC Filing on Google Icon
11/15/2024Soros Fund Management LLC30,000$0.78M0.0%N/A0.090%Search for SEC Filing on Google Icon
11/15/2024RA Capital Management L.P.1,511,334$39.26M0.5%N/A4.522%Search for SEC Filing on Google Icon
11/15/2024Point72 DIFC Ltd24,011$0.62M0.0%N/A0.072%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.15,600$0.41M0.0%N/A0.047%Search for SEC Filing on Google Icon
11/15/2024Maven Securities LTD50,000$1.30M0.0%N/A0.150%Search for SEC Filing on Google Icon
11/15/2024Point72 Asia Singapore Pte. Ltd.10,706$0.28M0.1%N/A0.032%Search for SEC Filing on Google Icon
11/14/2024NEA Management Company LLC3,614,486$93.90M5.1%N/A10.816%Search for SEC Filing on Google Icon
11/13/2024The Manufacturers Life Insurance Company46,194$1.20M0.0%N/A0.138%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
MBX Biosciences logo
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Read More on MBX Biosciences

Today's Range

Now: $21.89
Low: $20.55
High: $22.62

50 Day Range

MA: $20.88
Low: $15.94
High: $24.07

52 Week Range

Now: $21.89
Low: $15.31
High: $27.50

Volume

80,418 shs

Average Volume

178,013 shs

Market Capitalization

$731.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of MBX Biosciences?

MBX Biosciences' top insider shareholders include:
  1. Life Sciences X LP Frazier (Major Shareholder)
  2. Edward T Mathers (Director)
Learn More about top insider investors at MBX Biosciences.

Who are the major institutional investors of MBX Biosciences?

MBX Biosciences' top institutional shareholders include:
  1. Frazier Life Sciences Management L.P. — 17.91%
  2. NEA Management Company LLC — 10.82%
  3. Wellington Management Group LLP — 8.79%
  4. RA Capital Management L.P. — 4.52%
  5. Franklin Resources Inc. — 1.35%
  6. Maven Securities LTD — 0.15%
Learn More about top institutional investors of MBX Biosciences stock.

Which institutional investors are buying MBX Biosciences stock?

In the previous quarter, MBX stock was purchased by institutional investors including:
  1. Frazier Life Sciences Management L.P.
  2. NEA Management Company LLC
  3. Wellington Management Group LLP
  4. RA Capital Management L.P.
  5. Franklin Resources Inc.
  6. Maven Securities LTD
  7. The Manufacturers Life Insurance Company
  8. Soros Fund Management LLC
During the last year, these company insiders have bought MBX Biosciences stock:
  1. Life Sciences X LP Frazier (Major Shareholder)
  2. Edward T Mathers (Director)
Learn More investors buying MBX Biosciences stock.
How Low-Cost Stocks Generate Monthly Income
From Darwin   |   Ad
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
👉 Yes, I Want the Free Report! 👈